TRCT
ARRY

Tower Research Capital (TRC)’s Array Biopharma Inc ARRY Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,007
Closed -$15K – 4686
2018
Q3 		$15K Buy
+1,007
New +$15.4K ﹤0.01% 2541
2018
Q1 		– Sell
-4,658
Closed -$60K – 4188
2017
Q4 		$60K Sell
4,658
-23,860
-84% -$271K 0.01% 1196
2017
Q3 		$351K Buy
+28,518
New +$265K 0.03% 399
2017
Q2 		– Sell
-639
Closed -$6K – 3844
2017
Q1 		$6K Sell
639
-8,763
-93% -$93.2K ﹤0.01% 2152
2016
Q4 		$82K Buy
+9,402
New +$69.2K 0.01% 1080
2016
Q1 		– Sell
-5,624
Closed -$24K – 5345
2015
Q4 		$24K Buy
5,624
+2,266
+67% +$10.3K ﹤0.01% 1127
2015
Q3 		$15K Sell
3,358
-21,454
-86% -$127K ﹤0.01% 1998
2015
Q2 		$178K Buy
24,812
+16,493
+198% +$122K 0.02% 433
2015
Q1 		$61K Buy
8,319
+8,119
+4,060% +$57.8K 0.01% 1315
2014
Q4 		$1K Sell
200
-2,987
-94% -$11.8K ﹤0.01% 3805
2014
Q3 		$11K Sell
3,187
-1,813
-36% -$7.15K ﹤0.01% 2780
2014
Q2 		$23K Sell
5,000
-6,891
-58% -$28.5K ﹤0.01% 1773
2014
Q1 		$56K Buy
11,891
+4,139
+53% +$20.8K 0.01% 1012
2013
Q4 		$38K Sell
7,752
-7,330
-49% -$39.9K 0.01% 1641
2013
Q3 		$94K Buy
15,082
+14,816
+5,570% +$88K 0.01% 1360
2013
Q2 		$1K Buy
+266
New +$1.43K ﹤0.01% 3788

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Tower Research Capital (TRC)'s ARRY Position: Q4 2018 in Review

Tower Research Capital (TRC) sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 1,007 shares — an estimated $15K sold.

Tower Research Capital (TRC) first reported a position in ARRY in Q2 2013 and held it in 16 quarters. The position peaked at $351K in Q3 2017. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

  • Tower Research Capital (TRC) reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,007 Array Biopharma Inc shares in Q4 2018, an estimated $15K.
  • Tower Research Capital (TRC) first reported a position in Array Biopharma Inc in Q2 2013 and held it in 16 quarters.
  • Tower Research Capital (TRC)'s Array Biopharma Inc position peaked at $351K in Q3 2017.
  • 236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2018, filed 14 Feb 2019.